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New derivatives of E-6,t {compound CA-030 and CA.074] were tested in vitro and in rive for selective inhibition ol'cath~psin B. They e~hibiled 
10000,~-~t0000 tim¢~ ureat~r inhibitory effects on purified rat cathepsin B than on cathepsin H and t.: tlt¢ir initial A; values for cath~psin B were 
about 35  aM. like that of E.64-c, whereas their initial K, values for eathepsins H and Lwcre about 40°.200/aM, In in rive conditions, such as 
intrap¢,riton~al inj~tion of c~mpound CA-030 or CA.O'/4 into r, ts. compound CA.074 is an especially potent ~lcetivo inhibitor of cathel~in B. 
whereas compound CA.030 dues not show selectivity rot catltepsin B, althou~,h both compounds CA.030 and CA.074 show complete selectivity 
rot cathepsin B in vitro. 
Cysleinc proteinasc inhibitor~/E.64 derivative; Catllepsin B; Cathepsin L; Calhepsin H; Cysteine proteinase 
1. INTRODUCTION 
t.ysosomal cathepsins B, H and L are welL- 
characterized cysteine proteinases that are important in 
intracellular protein degradation [1,2]. Furthermore, 
cathepsins B and L may be invoh, ed in muscular 
dystrophy [3-5], bone resorption [6], pulmonary em- 
physema [7,8] and tumor invasion [9]. In establishing 
the individual roles of lysosomal cathepsins in these and 
other biological phenomena, the discovery of selective 
inhibitors has been and will be of critical importance. 
E-64 is an irreversible inhibitor of cysteine protemases 
isolated by Hanada et al. [10]. E-64 and its derivatives 
cause rapid inactivation of almost all cysteine pro- 
teinases [11-13]. Previously we have examined the 
mechanism of inhibition of cathepsins B and L by E-64 
and the potent inhibitory activities of E-64 and its 
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Abbreviations: Z, benzyloxycarbonyh MCA, ntethylcoulnarylamide: 
BCA, bicinchoninic acid', E.64-a, N.(L.3-trans.carboxyoxirane. 
2.carbonyl).L.leucine-4-aminobutylamide; E.64-c, N-(L.3.trans. 
carboxyoxirane-2-carbonyl)-L-leucine-3-methylbutylamide; CA-028, 
N- (L- 3 -trans- carboxyoxirane.2-carbonyl).L- isoleucyl - L-protine; 
CA-030 N-(L-3.trans-Etl~oxycarbonyloxirane.2.carbonyl).L-isoleu. 
cyl-L-proline; CA-074, N. (L-3-trans.Propylcarbamoyloxirane-2-car. 
bonyl)-L-isolcucyl-L-13roline; tES, L.trans.epo×ysueeinyl; [AA, lso. 
amylamide; Pr"NH mpropylamide 
Enzymes: cathepsin B, EC 3,4,22,1; cathepsin H, EC 3,4,22,16; 
cathepsin L, EC 3.4.22,15 
derivatives in rive [14,15]. We found that these com- 
pounds inactivated cathe psins B and L more powerfully 
than cathepsin H, but did not cause their selective in- 
hibition in vitro and in rive. Therefore, we searched for 
selective inhibitors of lysosomal cystcina proteinases in- 
cluding calpain and discovered new selective inhibitors, 
derivatives of  E-64, of cathepsin B in vitro. The 
characteristics of these inhibitors are described by 
Murata et al. [16]. In this paper, we report the specifici- 
ty of tt~e novel derivatives of E-64, compound CA-030 
and CA-074, for cathepsins B, H and L in vitro and in 
vivo, 
2. MATERIALS AND METHODS 
2.1. Materials 
Wistar rats, weighing 200-220 g were used for in rive studies. Rat 
liver cathepsins B, H and L were purified as described previously 
[l l, 17,18] with the additional purification steps on HPLC an TSK gel 
G3000 SW (Tokyo Soda) and Con A.Sepharose, Z-Phe.Arg-MCA, Z- 
Arg-Arg-MCA and Arg-MCA were purchased from tl~e Peptid¢ In- 
stilt|re (Osaka, Japan), All other chemicals were of analytical 8fade, 
E-64-n and E-64-c were products of Taisho Pharmaceutical Co. 
(Tokyo, Japan). The new derivatives orE-d4, compounds CA-028 = 
N- (L - 3 - irons, carboxyoxirane. 2- car bonyl) - L - isoleucyI. L- proli ne, 
CA-030 = N.(L-3.trans.ethoxycarbonylo×irane-2.earbonyl).L-iso- 
leucyl.L-proline and CA-074 = N.(L-3-trans.propylcarbamoyloxi- 
rane.2-carbonyl)-L.isoleucyl-L.proline, wer  prepared by M, Murata 
et al, as described previously [16], 
2,2, Methods 
2,2,1. Enzyme asays 
Cathepsin activities were assayed with Z-Arg-Arg-MCA at pH 6,0 
for cathepsin B, Arg-MCA at pH 7.0 for cathepsin H and Z-Phe.Arg- 
Published by Elsevier Science Publishers B. V, 31 1 
Volume 280, number 2 FEB8 LETTERS March 1991 
Table I 
Initial A', valu~ or |!.64.¢ and compotmds CA,0~0 and CA.0'/4 for rat ~tl~¢pstns B, H #rid L 
Compound Slrttctui'¢ 
E.64.¢ HO.t~$.LeudAA 
CA,0211 HO.tES.II¢.Pro.OH 
CA.030 EtO.tES.ile.Pro.OH 
CA,074 Pr" NH,tES-lle.Pro.OH 
Kt (x  I0 =~ MI 
Cmhepsin B Cathepsln H Cathepsin L 
11.70 111 3.$ 
H0,00 I HI~ 625 
4.Mr 42 9t)0 40 000 
1,94 '15 000 233 000 
Initial K, values (after $ rain or Incubation or enxyme with the inhibitor) were determined by Linewe'avcr.Burk double.reeip¢o~l plots as described 
in the Materials and Me|hods, 
MCA al pH $.5 for ¢atltepsln L as substrates by th~ method of Barrett 
arid Kirschke 119]. For studies of inhibitor kinetics, the activity of 
each proteinase was adjusted to 0.~ units tone unit or enzyme activity 
is defined as that releasing I nmo| of ?.amino.4.methylcoumarin per
rain at 37~C). Inhibitors were preineubated with enzyme for 5 rain 
and then reactions were started by addition of the substrate, Th© 
fluorescence of 7,amino,4.melhylcoumarin liberated from the 
substrate was monitored in a Hitachi fluorescence spectrometer, 
model 650-105 equipped with a recorder, Enlission at 460 nm was 
measured with excitation at 370 nm, The Ki values for inhibitors were 
determined from double.reciprocal Lineweaver-Burk plots, Five or 
six concentrations ofsubstrate that gave evenly distributed values of 
reciprocal values were used. 
2,2.2, Inhibition of cathepsin B, H and L by compounds CA.074, 
CA.030 and E.64.a in vivo 
Compound CA-074 or CA.030 or E.64.a was injected in- 
traperitoneally asa solution in saline containing DMSO at the doses 
indicated in the legends to Figure and Tables. In in vivo studies, adose 
of 8 mg/100 g body weight was injected. The rats were killed by a 
blow to the head 6 h after the injection, and their liver was perfused 
with saline, removed, weighed and chilled on ice. Samples of 4 g of 
liver were minced and homogenized in 7 vols of cold 0,25 M sucrose. 
The homogenate was centrifuged at 800 x g for 15 rain and the super. 
natant was centrifuged at 12 000 x g for 30 rain, The precipitate 
(crude mitochondrial.lysosomal fr ction; ML fraction) was suspend. 
ed in 2 ml of 0,05 M acetate buffer, pH 5,0, and freeze.thawed for 
measurements of cathepsin B, H and L activities, 
2.2,.4, HPLC profiles of eathepsins B, H and L in ML fractions 
treated with compounds CA.074 and E.64.a 
ML fractions from 4 g of liver of rats treated i.p. with saline, E-64-~ 
or compound CA.0T4. were freez©.thawed twice in 3.$ ml or o.05 M 
acetate buffer, pH 4.0, containln~ 0.S M NaCI. Each sample was 
dialyzed overnfght against I liter of 0,05 M acetate buffer, pH 4,0, ad. 
justed to 5.5 ml with the same buffer and cen|rlfu=ed for 10 rain at 
16 000 x g, Then volumes of 0.9 ml of the supernatant were applied 
to TSK SP 5PW columns [8 x 75 mini that had been equilibrated with 
0,05 M acetate buffer, pH 4.0. Each cohtmn was washed with the 
same buffer (5 ml) and then the bound protein was eluted with a linear 
ftradient formed with 15 ml of equilibration buffer and 15 ml of 0,9 
M NaCl, 0.05 M acetate buffer, pH 4,0 at a flow rate of 0.5 mllmin, 
Fractions of 0,5 ml were collected and their cathepsin B, H and L ac- 
tivities were assayed. 
Protein concentrations were. determined by the BCA method 
(Pierce Chemical Co,) with bovine serum albumin as a standard, 
3, RESULTS AND DISCUSSION 
3, 1. Inhibition kinetics o f  purif ied cathepsins B, H and 
L by compounds CA-028, CA.030, CA-074 and 
E-64-c 
In Tab le  I, the inh ib i to ry  act iv i t ies o f  compounds  
CA-028 ,  CA-030  and CA-074 on pur i f ied  rat ca theps ins  
B, H and  L are  compared  wi th  those o f  E -64 .c  wh ich  is 
a l so  a synthet i c  der ivat ive  o f  E-64 and  has been  
character i zed  [201. Compounds  CA-030  and CA-074 
were  s t ronger  inh ib i to rs  o f  catheps ins  B than E-64-c .  
Moreover ,  they  inh ib i ted  catheps in  B 10 000-30  000 
t imes  more  than  catheps in  H or L. Inh ib i t ion  a f ter  5 
min  was  dose-dependent :  the init ia l  K i  va lues  for  
Table I1 
Inhibitory effects of E-64-a and compounds CA.074 and CA-030 on Z-Phe-Arg-MCA, Z-Arg-Arg-MCA and Arg-MCA hydrolyzing activities in 
vivo 
Activities 
Compound Z-Phe-Arg-MCA Z-Arg-Arg-MCA Arg-MCA 
(pH 5.5) (pH 6,0) (pH 7,0) 
(Units/mg) (Units/rag) (Units/rag) 
Exp 1 
Control 78,65 ± 5.96 (100%) 8.38 ± 0,59 (100O7o) 6.35 ± 0,72 (10007o) 
E-64-a 6,03± 1,81 (7.7070) 0.18±0,10 (2,1O7o) 0.31 ±0.16 (5.0070) 
CA-074 46,83 ± 13,29 (59.5°70) 0.74±0,30 (8.0°70) 7.87 ± 1,60 (123,9o7o) 
Exp 2 
Control 62,53 ± 2.58 (100%) 4.19 ~- 0,45 (100O7o) 4.12 ± 0.34 (100°7o) 
E-64-a 2.81 :t:0,37 (4,5070) 0.08±0.03 (1,9o7o) 0.15±0.04 (3,6070) 
CA-030 17,27 ± 2,22 (27.607o) 0.54 ± 0,17 (12.9070) 1.43 ± 0.35 (34,7070) 
Rats were treated i.p. with 8 mg of E-64-a or compound CA-074 or CA-030 and 6 h later, ML fractions of livers were prepared for assays of Z-Phe- 
Arg-MCA, Z-Arg-Arg-MCA and Arg-MCA hydrolyzing activities, Values are means for 5 rats. 
312 
Vol.me 21~0, number 2 F l~ L~TTi~R~ Mar¢l~ 1~)91 
i 
(a) Control 
0 1 
10 
Z' { ] ~, 
i , 
g " ~ j ~ 2  ° '° '° - 
!9°1 / ~ 40,,~-Io,~ 
Fraction Number 
-g 
ol 
2 
~ A  / I  ~ 
O 10 20 3 8O 
1,0 
0.5 I 
z 
Z 
Fraction Humber 
Fig. I HPLC profiles of cathepsin B, H and L activities in ML fractions of liver of rats treated with saline, E.64-a or compo~md CA-074, Rats 
were treated i.p, with 8 mg of E-64-a or compound CA.074 and killed 6 h later and ML fractions were prepared as for Table II. After dialysis, 
samples from (a) a control rat (2.8 mg protein in 0.9 ml) and rats trealed with (b) E-64-a (3,0 mg protein in 0.9 ml) and (c) compound CA.074 
(2.8 mg protein in 0.9 ml) were subjected to HPLC on TSK SP 5PW (Toyo Soda) and Z-Phe-Arg-MCA (*--®), Z-Arg-Arg..MCA (o--o) and Arg- 
MCA (X--X) hydrolyzing activitites were assayed as described in the Materials and Methods, except hat in (c) Z-Phe-ArB-MCA hydrolyzing ac- 
tivities were assayed in the presence ( , _o )  and absence (o_6) of 100 nM E-64-c, Absorbance at 280 nnl (----) is also shown, 
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cathep~in B were about 2-~ aM, like that of E.64-¢, 
Whereas initial Ki values for cathepsln H and L were 
about 40-200 taM, These results sugjest that com- 
pounds CA.030 and CA.074 are potent selective in- 
hibitors of cathepsin B in vffro. 
3,2, Inactivation of  cathepsins B, H and L hy com- 
pounds CA.074. CA.030 anti £.6#.a in vivo 
In in vivo studies using E-64, E-64.a and E.64-e, 
cathepsins L and B were inactivated very effectively 
[15], On the other hand, it was predicted that com- 
pound CA-030 might be converted to compound 
CA.028 by hydrolysis of  the ethylester bond, in vivo, 
Practically, compound CA-030 did not show selective 
inactivation of  cathepsin B in vivo (Table 11), Com. 
pound CA-074 was designed with a modification to 
protect its attack by esterascs. We examined whether it 
is actually incorporated in the iysosomal fraction of the 
liver as the intact form and inhibits lysosomal cathepsin 
B specifically. 
Compounds CA.074, CA.030 and E-64-a (8 rag/100 
g rat) were injected i.p, into rats, (A dose of  I mg of  
E-64 per 100 g body weight has been found to be effec. 
tire on rat cathepsin B [1513 Six hours later, the animals 
were killed for measurements of cathepsin B, H and L 
activities in the crude ML fraction of the liver and the 
HPLC profiles of cathepsin B, H and L activities in ML 
fractions as described in Materials and Methods. As can 
be seen from Table ll at doses of gmg per 100 g body 
weight, E-64-a and compound CA-030 inactivated 
cathepsin B, H and L, whereas compound CA-074 inac- 
tivated cathepsin B selectively. Thus compound CA-074 
can be used as an effective selective inactivator of 
cathepsin B both in vivo and in vitro. 
3,3, HPLC profiles of  cathepsins B, H and L in ML 
fractions o f  ruts treated with compounds CA-074 
and E-64-a 
As Z-Phe-Arg-MCA is a substrate for both cathepsm 
B and L, to determine whether the remaining Z-Phe- 
Arg-MCA hydrolyzing activity in rats treated with com- 
pound CA-074 was due only to cathepsin L activity, we 
examined theHPLC profiles of cathepsins B, H and L 
as described in Materials and Methods. As shown in 
Fig. 1, in the preparation from the control rat, the main 
peak of cathepsin B activity was eluted with 0,44 M 
NaCI and those of  cathepsin H and L were elutecl with 
0.33 M and 0.70 M NaC1, respectively. The preparation 
from the rat treated with E-64-a gave very small peaks 
of  Z-Phe-Arg-MCA hydrolyzing activity eluted with 
various concentrations of  NaCI but no peaks in the 
positions of cathepsin B and cathepsin L, and Z-Arg- 
Arg°MCA and Arg-MCA hydro!ysing activities were in- 
activa ted completely. In contrast, the preparation f rom 
the rat treated with compound CA-074 gave peaks o f  Z- 
Phe-Arg-MCA hydrolyzing activity eluted in the posi- 
tions of cathepsins B and L. Recently, we have purified 
a novel hilili molecular ey~teine proteina~e located in 
ly~o~omes that Ires low affinity for E-64 [21]. To deter, 
mine whether the Z-Phe.Arli-MCA hydrolyxtnw activity 
remaininit in the eathepsin B frae|ion is due to thi~ high 
molecular cysteine protelnase or ~athep~in B~ we ex. 
trained the inhibitory effect ot' E-64.~; on remaininl~ Z- 
Phe-Arg.MCA ffydrolyzing activities in rats treated 
with compound CA-074 by in vitro assay. Results show. 
ed that 100 nM E.64.c caused complete inhibition of 
cathepsin L. but only partial inhibition of  remaining Z- 
Phe-Arg-MCA hydrolyzin8 activity in the cathepsin B 
fraction, Thus wc concluded that in the preparation 
from rats treated with compound CA-074 one peak of  
remaining Z-Phe.-Arg-MCA hydrolyzing activity was 
atributable to the novel high molecular weight cysteine 
prOteinase and the other tocathepsln L, Under tliese in 
vivo conditions, the Arg .MCA hydrolysing activity was 
not inactivated, as shown in Table II and Fig, It, 
Recently, the synthesis of  selective cysteine proteinase 
inhibitors has been attempted [22-24], Our results show 
that compound CA-074 is the first potent selective in- 
hibitor of cathepsin B both in vivo and in vitro. 
Therefore it could be useful in studies on the selective 
role of catlaepsia B in biological phenomena nd in- 
tracellular protein degradation processes 
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